PDE5 inhibitors as monotherapy have demonstrated significant therapeutic value in treating LUTS and ED in BPH patients, with demonstrated improvements in urinary flow and reported erectile function [29]. This evidence concerns the gene PDE5A and benign prostatic hyperplasia.